The warning bears repeating, and the FDA is repeating it. Counterfeit and unapproved toxins and fillers sold online can be contaminated, mis-dosed, or fake, with serious consequences including botulism.
The FDA has continued warning that counterfeit and unapproved botulinum toxin and filler products sold through websites can be adulterated, contaminated, improperly stored, or ineffective, raising the risk of serious harm including botulism. Both clinicians and consumers are urged to use authorized supply chains and report adverse events to MedWatch.
Some safety messages are worth repeating because the risk does not go away, and the FDA is repeating this one.
Recent coverage reiterated the dangers of unapproved injectables sold online.
Coverage in early June 2026 reiterated the FDAs ongoing warnings about websites illegally marketing unapproved and misbranded botulinum toxin products, often disguised as familiar brands, along with imported dermal fillers. The agency has cautioned that products obtained from unauthorized sources may be adulterated, contaminated, improperly stored, or ineffective, and that improper handling or dosing increases the risk of severe neurologic adverse events, including botulism. Many offending sellers require no prescription or credentials to purchase, a clear marker of an unauthorized channel.
The underlying issue is supply-chain integrity. Legitimate injectables move through authorized trading partners and carry required labeling and product identifiers; products bought from websites, social media, or messaging apps bypass those safeguards. The FDA urges clinicians to confirm that all injectable neurotoxins are procured through verified supply chains, and both professionals and consumers to report suspected adverse events to MedWatch.
For consumers, the repetition is the point: these are prescription products that belong with licensed providers using authorized supply, not items to buy online or receive from non-medical sellers. The documented risks, counterfeit contents, wrong dosing, contamination, and serious adverse events, are real. A low price or a buzzy product name is never worth an unverified source, and self-injection of such products is especially dangerous.
Expect continued enforcement against illicit sellers and unauthorized sourcing as a clear regulatory priority. For consumers, reliable safeguards endure: use licensed providers who source from authorized distributors; be wary of suspiciously cheap or unbranded products and unfamiliar packaging; avoid any offer to purchase injectables directly; and report suspected counterfeits or adverse events to the FDAs MedWatch program.